Switch theme
Sign up to access all valuation multiples
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
2011
385
LTM Revenue $296M
LTM EBITDA -$143M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Travere Therapeutics has a last 12-month revenue (LTM) of $296M and a last 12-month EBITDA of -$143M.
In the most recent fiscal year, Travere Therapeutics achieved revenue of $233M and an EBITDA of -$266M.
Travere Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Travere Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $296M | XXX | $233M | XXX | XXX | XXX |
| Gross Profit | $282M | XXX | $225M | XXX | XXX | XXX |
| Gross Margin | 95% | XXX | 97% | XXX | XXX | XXX |
| EBITDA | -$143M | XXX | -$266M | XXX | XXX | XXX |
| EBITDA Margin | -48% | XXX | -114% | XXX | XXX | XXX |
| EBIT | -$207M | XXX | -$321M | XXX | XXX | XXX |
| EBIT Margin | -70% | XXX | -138% | XXX | XXX | XXX |
| Net Profit | -$225M | XXX | -$322M | XXX | XXX | XXX |
| Net Margin | -76% | XXX | -138% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $320M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Travere Therapeutics's stock price is $15.
Travere Therapeutics has current market cap of $1.3B, and EV of $1.4B.
See Travere Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $1.3B | XXX | XXX | XXX | XXX | $-2.82 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Travere Therapeutics has market cap of $1.3B and EV of $1.4B.
Travere Therapeutics's trades at 6.1x EV/Revenue multiple, and -5.3x EV/EBITDA.
Equity research analysts estimate Travere Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Travere Therapeutics has a P/E ratio of -5.9x.
See valuation multiples for Travere Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV/Revenue | 4.8x | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBITDA | -9.8x | XXX | -5.3x | XXX | XXX | XXX |
| EV/EBIT | -6.8x | XXX | -4.4x | XXX | XXX | XXX |
| EV/Gross Profit | 5.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.9x | XXX | -4.1x | XXX | XXX | XXX |
| EV/FCF | 29.9x | XXX | -4.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTravere Therapeutics's last 12 month revenue growth is 55%
Travere Therapeutics's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $1.4M for the same period.
Travere Therapeutics's rule of 40 is -170% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Travere Therapeutics's rule of X is 89% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Travere Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 55% | XXX | 54% | XXX | XXX | XXX |
| EBITDA Margin | -48% | XXX | -114% | XXX | XXX | XXX |
| EBITDA Growth | -125% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -170% | XXX | -59% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 89% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 121% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 235% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Travere Therapeutics acquired XXX companies to date.
Last acquisition by Travere Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Travere Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Travere Therapeutics founded? | Travere Therapeutics was founded in 2011. |
| Where is Travere Therapeutics headquartered? | Travere Therapeutics is headquartered in United States of America. |
| How many employees does Travere Therapeutics have? | As of today, Travere Therapeutics has 385 employees. |
| Who is the CEO of Travere Therapeutics? | Travere Therapeutics's CEO is Dr. Eric M. Dube, PhD. |
| Is Travere Therapeutics publicy listed? | Yes, Travere Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Travere Therapeutics? | Travere Therapeutics trades under TVTX ticker. |
| When did Travere Therapeutics go public? | Travere Therapeutics went public in 2003. |
| Who are competitors of Travere Therapeutics? | Similar companies to Travere Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Travere Therapeutics? | Travere Therapeutics's current market cap is $1.3B |
| What is the current revenue of Travere Therapeutics? | Travere Therapeutics's last 12 months revenue is $296M. |
| What is the current revenue growth of Travere Therapeutics? | Travere Therapeutics revenue growth (NTM/LTM) is 55%. |
| What is the current EV/Revenue multiple of Travere Therapeutics? | Current revenue multiple of Travere Therapeutics is 4.8x. |
| Is Travere Therapeutics profitable? | Yes, Travere Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Travere Therapeutics? | Travere Therapeutics's last 12 months EBITDA is -$143M. |
| What is Travere Therapeutics's EBITDA margin? | Travere Therapeutics's last 12 months EBITDA margin is -48%. |
| What is the current EV/EBITDA multiple of Travere Therapeutics? | Current EBITDA multiple of Travere Therapeutics is -9.8x. |
| What is the current FCF of Travere Therapeutics? | Travere Therapeutics's last 12 months FCF is $47.2M. |
| What is Travere Therapeutics's FCF margin? | Travere Therapeutics's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Travere Therapeutics? | Current FCF multiple of Travere Therapeutics is 29.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
